Silibinin inhibits osteoclast differentiation mediated by TNF family members

Silibinin is a polyphenolic flavonoid compound isolated from milk thistle (Silybum marianum), with known hepatoprotective, anticarcinogenic, and antioxidant effects. Herein, we show that silibinin inhibits receptor activator of NF-κB ligand (RANKL)-induced osteoclastogenesis from RAW264.7 cells as well as from bone marrow-derived monocyte/macrophage cells in a dose-dependent manner. Silibinin has no effect on the expression of RANKL or the soluble RANKL decoy receptor osteoprotegerin (OPG) in osteoblasts. However, we demonstrate that silibinin can block the activation of NF-κB, c-Jun N-terminal kinase (JNK), p38 mitogen-activated protein (MAP) kinase, and extracellular signal-regulated kinase (ERK) in osteoclast precursors in response to RANKL. Furthermore, silibinin attenuates the induction of nuclear factor of activated T cells (NFAT) c1 and osteoclast-associated receptor (OSCAR) expression during RANKL-induced osteoclastogenesis. We demonstrate that silibinin can inhibit TNF-α-induced osteoclastogenesis as well as the expression of NFATc1 and OSCAR. Taken together, our results indicate that silibinin has the potential to inhibit osteoclast formation by attenuating the downstream signaling cascades associated with RANKL and TNF-α.

• Publication year

  2009

• Venue

  Molecules and Cells

• Publication date

  2009-09-04

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/s10059-009-0123-yPMID 19756392
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• AG490, a Jak2-specific inhibitor, induces osteoclast survival by activating the Akt and ERK signaling pathways.

  2008cited by this paper
• NFATc1 induces osteoclast fusion via up-regulation of Atp6v0d2 and the dendritic cell-specific transmembrane protein (DC-STAMP).

  2008cited by this paper
• Multitargeted therapy of cancer by silymarin.

  2008cited by this paper
• MafB negatively regulates RANKL-mediated osteoclast differentiation.

  2007cited by this paper
• Id helix-loop-helix proteins negatively regulate TRANCE-mediated osteoclast differentiation.

  2006cited by this paper
• The roles of Akt and MAPK family members in silymarin's protection against UV-induced A375-S2 cell apoptosis.

  2006cited by this paper
• Brief Definitive Report : Osteoclast differentiation independent of the TRANCE-RANK-TRAF6 axis

  2006cited by this paper
• Osteoimmunology: interplay between the immune system and bone metabolism.

  2006cited by this paper
• Nuclear Factor of Activated T Cells c1 Induces Osteoclast-associated Receptor Gene Expression during Tumor Necrosis Factor-related Activation-induced Cytokine-mediated Osteoclastogenesis*

  2005cited by this paper
• Silibinin strongly inhibits growth and survival of human endothelial cells via cell cycle arrest and downregulation of survivin, Akt and NF-κB: implications for angioprevention and antiangiogenic therapy

  2005cited by this paper
• Osteoclast differentiation independent of the TRANCE–RANK–TRAF6 axis

  2005cited by this paper
• Mechanisms and preclinical efficacy of silibinin in preventing skin cancer.

  2005cited by this paper
• Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis

  2004cited by this paper
• Osteoimmunology: interactions of the immune and skeletal systems.

  2004cited by this paper
• Osteoclast differentiation and activation

  2003cited by this paper
• Signal transduction by receptor activator of nuclear factor kappa B in osteoclasts.

  2003influential reference
• Dietary feeding of silibinin inhibits advance human prostate carcinoma growth in athymic nude mice and increases plasma insulin-like growth factor-binding protein-3 levels.

  2002cited by this paper
• A Novel Member of the Leukocyte Receptor Complex Regulates Osteoclast Differentiation

  2002cited by this paper
• Flavonoid Antioxidant Silymarin and Skin Cancer

  2002cited by this paper
• Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts.

  2002influential reference
• Tumor Necrosis Factor- (cid:1) Supports the Survival of Osteoclasts through the Activation of Akt and ERK*

  2001cited by this paper
• Tumor Necrosis Factor (cid:97) Stimulates Osteoclast Differentiation by a Mechanism Independent of the ODF/RANKL–RANK Interaction

  2000cited by this paper
• Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand.

  1999cited by this paper
• Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families.

  1999cited by this paper
• Silymarin suppresses TNF-induced activation of NF-kappa B, c-Jun N-terminal kinase, and apoptosis.

  1999cited by this paper
• Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.

  1998cited by this paper
• Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL.

  1998cited by this paper
• Role of 1 alpha,25-dihydroxyvitamin D3 in osteoclast differentiation and function.

  1997influential reference
• [On the pharmacology and toxicology of silymarin, an antihepatotoxic active principle from Silybum marianum (L.) Gaertn].

  1968cited by this paper

• Effects of silybin on triptorelin-induced bone metabolic abnormalities in prostate cancer revealed based on TMT-based proteomics

  2026cites this paper
• Foliar spraying with zinc oxide nanoparticles enhances the anti-osteoporotic efficacy of the fruit extracts of Silybum marianum L. by stimulating silybin production

  2025cites this paper
• The Effects and Safety of Silymarin on β-thalassemia in Children and Adolescents: A Systematic Review based on Clinical Trial Studies.

  2024cites this paper
• Silibinin alleviates inflammation-induced bone loss by modulating biological interaction between human gingival fibroblasts and monocytes.

  2023cites this paper
• A review on phytoestrogens: Current status and future direction

  2023cites this paper
• Inhibition of Phagocytosis by Silibinin in Mouse Macrophages

  2023cites this paper
• Phytochemicals in Breast Cancer-Induced Osteoclastogenesis and Bone Resorption: Mechanism and Future Perspective

  2022cites this paper
• Phytochemicals in Breast Cancer-Induced Osteoclastogenesis and Bone Resorption: Mechanism and Future Perspective

  2022cites this paper
• Controlled release of silibinin in GelMA hydrogels inhibits inflammation by inducing M2-type macrophage polarization and promotes vascularization in vitro

  2022cites this paper
• KYMASIN UP Natural Product Inhibits Osteoclastogenesis and Improves Osteoblast Activity by Modulating Src and p38 MAPK

  2022cites this paper
• Role of OSCAR Signaling in Osteoclastogenesis and Bone Disease

  2021cites this paper
• Emerging Natural-Product-Based Treatments for the Management of Osteoarthritis

  2021cites this paper
• Potential Advantages of Bioactive Compounds Extracted From Traditional Chinese Medicine to Inhibit Bone Destructions in Rheumatoid Arthritis

  2020cites this paper
• A mechanistic insight of phytoestrogens used for Rheumatoid arthritis: An evidence-based review.

  2020cites this paper
• Modulatory effects of silibinin in cell behavior during osteogenic phenotype

  2019cites this paper
• Local administration with silymarin could increase osseointegration of hydroxyapatite-coated titanium implants in ovariectomized rats

  2019cites this paper
• Potentials of Polyphenols in Bone-Implant Devices

  2018cites this paper
• Chapter 4 Potentials of Polyphenols in Bone-Implant Devices

  2018cites this paper
• Dietary nutraceuticals as backbone for bone health.

  2018cites this paper
• The Incorporation of Strontium to Improve Bone-Regeneration Ability of Mesoporous Bioactive Glasses

  2018cites this paper
• Molecular signaling mechanisms behind polyphenol-induced bone anabolism

  2017influential citation
• The protective effects of silibinin in the treatment of streptozotocin-induced diabetic osteoporosis in rats.

  2017cites this paper
• Emerging Importance of Phytochemicals in Regulation of Stem Cells Fate via Signaling Pathways

  2017cites this paper
• Silibinin: An Inhibitor of Mir-181a Gene Expression in Sk-Br-3 Breast Cancer Cell Line

  2017cites this paper
• Magnaporthe oryzae Effector AVR-Pii Helps to Establish Compatibility by Inhibition of the Rice NADP-Malic Enzyme Resulting in Disruption of Oxidative Burst and Host Innate Immunity

  2016cites this paper
• Silymarin Inhibits Morphological Changes in LPS-Stimulated Macrophages by Blocking NF-κB Pathway

  2015influential citation
• Silibinin alleviates high glucose-suppressed osteogenic differentiation of human bone marrow stromal cells via antioxidant effect and PI3K/Akt signaling.

  2015cites this paper
• Silibinin inhibits prostate cancer cells‐ and RANKL‐induced osteoclastogenesis by targeting NFATc1, NF‐κB, and AP‐1 activation in RAW264.7 cells

  2014cites this paper
• Evaluation of the Effect of Silymarin Alone and in Combination with Calcium on Bone Formation, Resorbtion and Turn over in Ovariohysterectomized Rat Model

  2014cites this paper
• SLAT negatively regulates RANKL-induced osteoclast differentiation

  2013cites this paper
• Targeting tumor microenvironment with silibinin: promise and potential for a translational cancer chemopreventive strategy.

  2013cites this paper
• Silibinin Inhibits LPS-Induced Macrophage Activation by Blocking p38 MAPK in RAW 264.7 Cells

  2013influential citation
• Acteoside Suppresses RANKL-Mediated Osteoclastogenesis by Inhibiting c-Fos Induction and NF-κB Pathway and Attenuating ROS Production

  2013cites this paper
• Mediators of Inflammation-Induced Bone Damage in Arthritis and Their Control by Herbal Products

  2013influential citation
• Silibinin promotes osteoblast differentiation of human bone marrow stromal cells via bone morphogenetic protein signaling.

  2013cites this paper
• Isolation and identification of RANKL-induced osteoclast differentiation inhibitor from Pleurotus citrinopileatus

  2013cites this paper
• Osteoblastogenesis and osteoprotection enhanced by flavonolignan silibinin in osteoblasts and osteoclasts

  2012cites this paper
• Screening of Bioactive Compounds from Edible Mushroom and Production of Anti-osteoporosis Osteoclast Differentiation Inhibitor

  2012cites this paper
• Inhibitory effect of ursane-type triterpenoids from Weigela subsessilis on RANKL-induced osteoclast differentiation

  2011cites this paper
• The Role of Osteoclast-Associated Receptor in Osteoimmunology

  2011cites this paper
• The Role of Osteoclast-Associated Receptor

  2010cites this paper
• This information is current as NFATc 1 Induction B Activation and κ Osteoclastogenesis via NF-Pim-1 Regulates RANKL-Induced and Nacksung

  2010cites this paper
• Antimetastatic efficacy of silibinin: molecular mechanisms and therapeutic potential against cancer

  2010influential citation
• Pim-1 Regulates RANKL-Induced Osteoclastogenesis via NF-κB Activation and NFATc1 Induction

  2010cites this paper